Category: St. Jude Medical
St. Jude Medical enters the spinal pain treatment arena with the $200 million cash acquisition of NeuroTherm and its radiofrequency ablation technology.
Minnesota-based medtech giant St. Jude Medical (NYSE:STJ) is broaching new ground in the spinal pain market with the $200 million acquisition of NeuroTherm, maker of radiofrequency ablation therapies.
Here's a look at some of the top regulatory stories for medical device companies this week: FDA aims to stay the course in new 4-year plan; Medical device recalls for June 2014; Medtronic issues Class I recall of Duet neuro drainage and monitoring systems; FDA warns Staar Surgical for missing documentation; FDA clears St. Jude Medical after 2013 warning letter
MassDevice.com speaks to 3M's Deb Rectenwald, St. Jude Medical's Philip Ebeling and Nadim Yared, CEO of CVRx, about the environment for M&A in medtech following the $43 billion Medtronic/Covidien deal.
A federal judge rules that most of the product liability claims against St. Jude Medical are preempted in a trio of lawsuits filed over its recalled Riata defibrillator leads.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
St. Jude Medical says the FDA cleared the Sylmar, Calif., plant that produces its Durata defibrillators leads following a warning letter issued early last year.